Piramal Pharma Receives ESG Rating of 61 from NSE Sustainability for FY24
Piramal Pharma Limited (PPLPHARMA) has received an Environment, Social, and Governance (ESG) Rating of '61' for the financial year 2023-24 from NSE Sustainability Ratings and Analytics Limited ('NSE Sustainability'). This rating, based on data made available by the company in the public domain, was disclosed by Piramal Pharma on July 10, 2025, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
ESG Rating DetailsParticulars
Details
Company
Piramal Pharma LimitedRating Agency
NSE Sustainability Ratings and Analytics LimitedESG Rating
61Period Assessed
FY 2023-24Basis of Rating
Publicly available dataCompany Engagement
Not engaged by the company (voluntarily prepared)Disclosure Date
July 10, 2025
Action Details and ContextPiramal Pharma Limited announced that it received information on July 08, 2025, regarding an ESG rating assigned by NSE Sustainability. The rating of '61' pertains to the company's performance during the financial year 2023-24. A significant aspect of this rating is that Piramal Pharma Limited did not engage NSE Sustainability for this assessment. Instead, NSE Sustainability voluntarily prepared the report, considering the ESG factors reported by the company in the public domain for the specified fiscal year. This voluntary assessment underscores an independent evaluation of the company's sustainability practices. The link for the published rating is also available on the website of NSE Sustainability, providing transparency and accessibility to the detailed assessment.Process and Regulatory ComplianceThe disclosure of this ESG rating by Piramal Pharma Limited is in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to disclose any event or information that is material to the company. While ESG ratings are increasingly becoming a crucial metric for investors and stakeholders, their formal disclosure under listing regulations highlights their growing importance in corporate governance and transparency. The company has also uploaded this intimation on its official website, ensuring broad dissemination of the information to its shareholders and the wider public. The process involved NSE Sustainability analyzing publicly available data, which includes annual reports, sustainability reports, and other disclosures made by Piramal Pharma, to arrive at the '61' rating.Significance of ESG RatingsESG ratings provide a comprehensive assessment of a company's performance across environmental, social, and governance parameters. For a pharmaceutical company like Piramal Pharma, environmental factors might include waste management, carbon emissions, and sustainable resource use. Social aspects could cover employee welfare, product safety, community engagement, and access to medicines. Governance typically involves board structure, executive compensation, business ethics, and shareholder rights. A rating of '61' indicates a certain level of performance in these areas, reflecting the company's commitment and efforts towards sustainable and responsible business practices. In today's investment landscape, ESG performance is increasingly influencing investment decisions, with a growing number of institutional investors integrating ESG criteria into their portfolio selection processes.Shareholder and Market ImpactWhile the immediate market impact of a specific ESG rating is not detailed in the disclosure, such ratings generally contribute to a company's overall perception among investors and stakeholders. A favourable or improving ESG rating can enhance a company's reputation, attract socially responsible investors, and potentially lead to a lower cost of capital. It signals to the market that the company is proactive in managing non-financial risks and opportunities, which can contribute to long-term value creation. For Piramal Pharma, this voluntary rating from a reputable entity like NSE Sustainability provides an external validation of its ESG efforts, potentially reinforcing investor confidence in its sustainability agenda. As ESG considerations become more mainstream, companies with strong ESG profiles are often viewed as more resilient and better positioned for future growth. This disclosure serves as an important update for shareholders and potential investors interested in the company's sustainability performance.